Trial results

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

NCT05877547 on ClinicalTrials.gov · last registry update 2026-01-12

An unusually large phase 2: 381 participants, more than double the 114 typical for the stage. The sponsor logged completion for 29 December 2025. Primary outcome, as filed: Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis At Week 52. semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

COMPLETED

Phase

P2

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Enrollment

381

Started

2023-06-23

Primary completion

2025-12-29 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis At Week 52

Conditions studied

Non-alcoholic Fatty Liver Disease · Fatty Liver, Nonalcoholic · NAFLD · Nonalcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.